Protocol Ledger

NCT04981717 · Phase III · TERMINATED

A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat

Interventional Phase III clinical trial protocol NCT04981717 sponsored by Regeneron Pharmaceuticals in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-07-30 Enrollment: 446 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04981717
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)446 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04981717
Protocol FieldVerified Registry Value
NCT IdentifierNCT04981717
Consolidated Lead SponsorRegeneron Pharmaceuticals
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment446 participants (ACTUAL)
Registered Start Date2021-07-30
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04981717
Hospital Research SiteLocationSite Profile
Emory Winship Cancer InstituteAtlanta, GAOpen Hospital Dossier ->
Velocity Clinical Research (Meridian)Meridian, IDOpen Hospital Dossier ->
Rush University Medical CenterChicago, ILOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Regeneron Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI